var data={"title":"Aspirin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aspirin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5673?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aspirin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aspirin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=aspirin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aspirin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137093\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ascriptin Maximum Strength [OTC];</li>\n      <li>Ascriptin Regular Strength [OTC];</li>\n      <li>Aspercin [OTC];</li>\n      <li>Aspir-low [OTC];</li>\n      <li>Aspirtab [OTC];</li>\n      <li>Bayer Aspirin Extra Strength [OTC];</li>\n      <li>Bayer Aspirin Regimen Adult Low Strength [OTC];</li>\n      <li>Bayer Aspirin Regimen Children's [OTC];</li>\n      <li>Bayer Aspirin Regimen Regular Strength [OTC];</li>\n      <li>Bayer Genuine Aspirin [OTC];</li>\n      <li>Bayer Plus Extra Strength [OTC];</li>\n      <li>Bayer Women's Low Dose Aspirin [OTC];</li>\n      <li>Buffasal [OTC];</li>\n      <li>Bufferin Extra Strength [OTC];</li>\n      <li>Bufferin [OTC];</li>\n      <li>Buffinol [OTC];</li>\n      <li>Durlaza;</li>\n      <li>Ecotrin Arthritis Strength [OTC];</li>\n      <li>Ecotrin Low Strength [OTC];</li>\n      <li>Ecotrin [OTC];</li>\n      <li>Halfprin [OTC] [DSC];</li>\n      <li>St Joseph Adult Aspirin [OTC];</li>\n      <li>Tri-Buffered Aspirin [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137094\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Asaphen;</li>\n      <li>Asaphen E.C.;</li>\n      <li>Entrophen;</li>\n      <li>Novasen;</li>\n      <li>Praxis ASA EC 81 Mg Daily Dose;</li>\n      <li>Pro-AAS EC-80</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137145\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Nonopioid;</li>\n      <li>\n        Antiplatelet Agent;</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;</li>\n      <li>\n        Salicylate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137098\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> For most cardiovascular uses, typical maintenance dosing of aspirin is 81 mg once daily. Manufacturer recommended dosing for some indications have been superseded by more recent guideline recommended doses and therefore manufacturer recommended dosing may not be represented; terminologies may also differ from manufacturer's prescribing information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute coronary syndrome (ST- elevation myocardial infarction [STEMI], non-ST-elevation acute coronary syndromes [NSTE-ACS]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> 162 to 325 mg given on presentation (patient should chew nonenteric-coated aspirin especially if not taking before presentation) (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]); for patients unable to take oral, may use a rectal suppository dose of 600 mg (Maalouf 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance (secondary prevention):</i> 81 to 325 mg once daily continued indefinitely; when aspirin is used with ticagrelor, the recommended maintenance dose of aspirin is 81 mg/day (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O&rsquo;Gara 2013]) According to the STEMI guidelines, 81 mg once daily is preferred (ACCF/AHA [O&rsquo;Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant antiplatelet therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">STEMI: Aspirin is recommended in combination with either clopidogrel, prasugrel, or ticagrelor given as early as possible or at time of PCI. In addition to dual antiplatelet therapy, parenteral anticoagulant therapy is indicated. Post-PCI stenting, consult clinical practice guidelines for recommended duration of maintenance antiplatelet therapy depending on type of stenting (ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">NSTE-ACS:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>If early-invasive strategy chosen:</i> Aspirin is recommended in combination with either clopidogrel or ticagrelor. In addition to dual antiplatelet therapy, parenteral anticoagulant therapy is indicated. In select high-risk patients (ie, troponin positive), an IV GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy (if given before PCI, eptifibatide and tirofiban are preferred agents). In patients post-PCI with stenting (bare metal or drug-eluting stent), aspirin should be given with either clopidogrel, ticagrelor, or prasugrel for at least 12 months (ACC/AHA [Amsterdam 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>If ischemia-guided strategy (ie, noninvasive strategy) chosen:</i> Aspirin is recommended in combination with clopidogrel or ticagrelor for up to 12 months In addition to dual antiplatelet therapy, parenteral anticoagulant therapy is indicated. (ACC/AHA [Amsterdam 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Analgesic and antipyretic: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: 325 to 650 mg as needed every 4 hours <b>or</b> 975 mg as needed every 6 hours <b>or</b> 500 to 1,000 mg as needed every 4 to 6 hours for no more than 10 days or as directed by health care provider; maximum daily dose: 4 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: 300 to 600 mg every 4 hours for no more than 10 days or as directed by health care provider</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory (off-label dosing): Note:</b> The use of non-aspirin NSAIDs has largely supplanted the use of aspirin for osteoarthritis, rheumatoid arthritis, and other inflammatory arthritides.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Oral: Usual maintenance dose: 2.1 to 7.3 g/day in divided doses (individualize dose); monitor serum salicylate concentrations especially when symptoms of salicylism (eg, tinnitus) appear; adjust dose accordingly (Csuka 1989).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aortic valve repair (off-label use):</b> Immediate release: Oral: 50 to 100 mg once daily (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation </b>\n      <b>(to prevent thromboembolism) (off-label use): </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary prevention:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients at low risk of ischemic stroke (CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1):</i> Immediate release: Oral: 75 to 325 mg once daily may be considered. <b>Note:</b> Data has shown that adjusted-dose warfarin for stroke prevention is significantly better than aspirin in combination with clopidogrel, and aspirin in combination with clopidogrel is superior to aspirin monotherapy (ACTIVE Investigators 2009; AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients unsuitable for or who choose not to take an oral anticoagulant (reasons other than bleeding concerns): </i>Immediate release: 75 to 100 mg once daily in combination with clopidogrel. <b>Note: </b>Oral anticoagulation (eg, warfarin) is preferred (ACTIVE Investigators 2009); aspirin in combination with clopidogrel may be used in patients who are at low bleeding risk (ACCP [You 2012]). The patient with an elevated bleeding risk who is not a candidate for oral anticoagulation would not be a candidate for dual antiplatelet therapy given the comparable risk of bleeding events (Connolly 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Secondary prevention following stroke or TIA in patients who are unable to take oral anticoagulants:</i> Immediate release: 75 to 100 mg once daily. Monotherapy with aspirin is recommended; addition of clopidogrel to aspirin might be reasonable (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Carotid artery stenosis (asymptomatic) (off-label use):</b> Immediate release: Oral: 75 to 100 mg once daily (ACCP [Alonso-Coello 2012]). <b>Note:</b> The addition of statin therapy has also been recommended for asymptomatic carotid stenosis (AHA/ASA [Meschia 2014]). When symptomatic, the use of clopidogrel or aspirin/extended-release dipyridamole has been suggested over aspirin alone (ACCP [Alonso-Coello 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Carotid endarterectomy (off-label dosing):</b> Immediate release: Oral: 75 to 100 mg once daily (ACCP [Alonso-Coello 2012]; AHA [Biller 1998]). The use of clopidogrel or aspirin/extended-release dipyridamole has been suggested over aspirin alone (ACCP [Alonso-Coello 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer risk reduction (off-label use):</b> <b>Note:</b> The optimal dose and duration of therapy for colorectal cancer risk reduction are unknown. Consider risk versus benefit ratio when initiating aspirin for this indication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary/Secondary prevention:</i> Immediate release: Oral: 75 to 325 mg once daily (Rothwell 2010; Sandler 2003; Ye 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hereditary nonpolyposis colon cancer (HNPCC; Lynch Syndrome) carriers:</i> Immediate release: Oral: 600 mg once daily for at least 2 years (ASCO [Stoffel 2014]; Burn 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coronary artery disease (CAD), established or chronic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release (off-label dosing): Oral: 75 to 100 mg once daily (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release capsule: Oral: 162.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention (PCI) (off-label dosing):</b> Immediate release: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-emergent PCI:</i> Preprocedure: 81 to 325 mg (325 mg [nonenteric coated] in aspirin-naive patients) starting at least 2 hours (preferably 24 hours) before procedure. Postprocedure: 81 mg once daily continued indefinitely (in combination with a P2Y<sub>12</sub> inhibitor [eg, clopidogrel, prasugrel, ticagrelor] up to 12 months) (ACCF/AHA/SCAI [Levine 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary PCI:</i> Preprocedure: 162 to 325 mg as early as possible prior to procedure; 325 mg preferred. Postprocedure: 81 mg once daily continued indefinitely (in combination with a P2Y12 inhibitor [eg, clopidogrel] for at least 14 days and up to 12 months) (ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternatively, in patients who have undergone elective PCI with either bare metal or drug-eluting stent placement:</i> The American College of Chest Physicians recommends the use of 75 to 325 mg once daily (in combination with clopidogrel) for 1 month in patients receiving a bare metal stent or 3 to 6 months (dependent upon drug eluting stent type) followed by 75 to 100 mg once daily (in combination with clopidogrel) for up to 12 months. For patients who underwent PCI but did not have stent placement, 75 to 325 mg once daily (in combination with clopidogrel) for 1 month is recommended. In either case, single antiplatelet therapy (either aspirin or clopidogrel) is recommended indefinitely (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pericarditis (off-label use):</b> Immediate release: Oral: Initial: 2.4 to 3.6 g daily in 3 to 4 divided doses; usual maintenance: 3.6 to 5.4 g daily in divided doses; gradually taper over 2- to 3-week period as appropriate (Imazio 2004; Imazio 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pericarditis in association with myocardial infarction (off-label use):</b> Immediate release: Oral: Initial: 650 mg 4 times daily; may increase after 24 hours to 975 mg 4 times daily if necessary (ACCF/AHA [O'Gara 2013]; Berman 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral arterial disease (off-label use): </b> Immediate release: Oral: 75 to 100 mg once daily (ACCP [Guyatt 2012]) <b>or</b> 75 to 325 mg once daily (AHA/ACC [Gerhard-Herman 2016]). The use in combination with clopidogrel may be considered in patients with symptomatic PAD after lower extremity revascularization (AHA/ACC [Gerhard-Herman 2016]). <b>Note:</b> These recommendations also pertain to patients with intermittent claudication or critical limb ischemia, prior lower extremity revascularization, or prior amputation for lower extremity ischemia (Rooke 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral artery percutaneous transluminal angioplasty (with or without stenting) or peripheral artery bypass graft surgery, postprocedure (off-label use):</b> Immediate release: Oral: 75 to 100 mg once daily (ACCP [Guyatt 2012]). <b>Note:</b> For below-knee bypass graft surgery with prosthetic grafts, combine with clopidogrel (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polycythemia vera (off-label use):</b> Immediate release: Oral: 75 or 100 mg once daily (Barbui 2006; McMullin 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pregnant women: </i>75 mg once daily (Barbui 2011; McMullin 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preeclampsia prevention (women at risk) (off-label use):</b> Immediate release: Oral: One low-dose aspirin daily. The definition of low-dose varies by guideline and study; recommended ranges are 75 mg (ACCP [Guyatt 2012]) to 150 mg once daily (Roberge 2017; Rolnik 2017). A dose of 100 to 150 mg once daily may be more effective than lower doses (Roberge 2017). Treatment is generally started ~12 weeks gestation; however, therapy initiated after 16 weeks gestation but prior to the development of symptoms is effective (Meher 2017; Roberge 2016; Roberge 2017). Most studies discontinue therapy at ~36 to 37 weeks gestation (Roberge 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention (primary) of cardiovascular disease (off-label use):</b> Immediate release: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Chest Physicians: Select individuals &ge;50 years (without symptomatic cardiovascular disease): 75 to 100 mg once daily (ACCP [Vandvik 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American Diabetes Association: Individuals &ge;50 years with diabetes (type 1 or 2) and at least one additional risk factor: 75 to 162 mg once daily (ADA 2018)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention (secondary) of cardiovascular disease (patients with diabetes) (off-label use): </b>Immediate release: Oral: 75 to 162 mg once daily (ADA 2018)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention (secondary) after coronary artery bypass graft (CABG) surgery (off-label dosing):</b> Immediate release: Oral: 81 to 325 mg once daily administered preoperatively and within 6 hours postoperatively; continue indefinitely. Following off-pump CABG, administer aspirin 81 to 162 mg in combination with clopidogrel for 12 months (AHA [Kulik 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic heart valve (thromboprophylaxis) (off-label use):</b> Immediate release: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bioprosthetic aortic valve (patient in normal sinus rhythm):</i> 50 to 100 mg once daily (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bioprosthetic aortic or mitral valve:</i> History of ischemic stroke or TIA before valve insertion and who are at a low risk of bleeding and no other indication for anticoagulation therapy beyond 3 to 6 months from the valve placement: 75 to 100 mg once daily is recommended in preference to long-term anticoagulation (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bioprosthetic mitral valve:</i> 50 to 100 mg once daily after 3 months of anticoagulation with warfarin (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mechanical aortic or mitral valve:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low risk of bleeding: 50 to 100 mg once daily (in combination with warfarin) (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">History of ischemic stroke or TIA before valve insertion and who are at a low risk of bleeding: 75 to 100 mg once daily (in combination with warfarin) (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients with an ischemic stroke or systemic embolism despite adequate antithrombotic therapy: 325 mg once daily (in combination with warfarin) (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pregnant women, mechanical or bioprosthetic:</i> 75 to 100 mg once daily during the second and third trimesters (when used for mechanical prosthetic valve, combine with warfarin) (AHA/ACC [Nishimura 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transcatheter aortic bioprosthetic valve:</i> 50 to 100 mg once daily (in combination with clopidogrel) (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stroke/TIA:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute ischemic stroke/TIA:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (off-label dosing): Initial: 160 to 325 mg within 48 hours of stroke/TIA onset, followed by 75 to 100 mg once daily (ACCP [Guyatt 2012]). The AHA/ASA recommends an initial dose of 325 mg within 24 to 48 hours after stroke; do not administer aspirin within 24 hours after administration of alteplase (Jauch 2013). The combination of aspirin and clopidogrel might be considered within 24 hours of a minor ischemic stroke or TIA and continued for 21 days (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release capsule: Maintenance (secondary prevention): 162.5 mg once daily. <b>Note:</b> Not for initial dosing during acute ischemic stroke or TIA (use immediate release)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardioembolic, secondary prevention (oral anticoagulation unsuitable) (off-label:</i> Immediate release: 75 to 100 mg once daily (in combination with clopidogrel) (ACCP [Guyatt 2012]; The ACTIVE Investigators [Connolly 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cryptogenic with patent foramen ovale (PFO) or atrial septal aneurysm (off-label use): </i> Immediate release: 50 to 100 mg once daily (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intracranial atherosclerosis (50% to 99% stenosis of a major intracranial artery), secondary prevention (off-label): </i>325 mg once daily (consider the addition of clopidogrel for 90 days in patients with recent stroke/TIA due to severe stenosis [70% to 99%]) (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Noncardioembolic, secondary prevention (off-label use):</i> Immediate release: 75 to 325 mg once daily (Smith, 2011) <b>or</b> 75 to 100 mg once daily (ACCP [Guyatt 2012]). <b>Note:</b> Combination aspirin/extended release dipyridamole or clopidogrel is preferred over aspirin alone (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Women at high risk for first stroke, primary prevention:</i> Immediate release: 81 mg once daily <b>or</b> 100 mg every other day (AHA/ASA [Meschia 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous thromboembolism, extended therapy to prevent recurrence (in patients who have completed anticoagulation treatment and decided to stop oral anticoagulation) (off-label use): </b>Oral: 100 mg once daily (Becattini 2012; Brighton 2012; Simes 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137119\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=aspirin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aspirin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not use aspirin in children &lt;12 years (APS 2008) and adolescents (per manufacturer) who have or who are recovering from chickenpox or flu symptoms due to the association with Reye's syndrome (APS 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Analgesic:</b> Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents weighing &lt;50 kg (off-label use): Oral, rectal: 10 to 15 mg/kg/dose every 4 to 6 hours; maximum daily dose: The lesser value of either 90 mg/kg/day or 4 g/day (APS 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents weighing &ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 325 to 650 mg as needed every 4 hours <b>or</b> 975 mg as needed every 6 hours <b>or</b> 500 to 1,000 mg as needed every 4 to 6 hours for no more than 10 days or as directed by health care provider; maximum daily dose: 4 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: 300 to 600 mg every 4 hours for no more than 10 days or as directed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory (off-label use):</b> Immediate release: Oral: Initial: 60 to 90 mg/kg/day in divided doses; usual maintenance: 80 to 100 mg/kg/day divided every 6 to 8 hours; monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antiplatelet effects (off-label use):</b> Adequate pediatric studies have not been performed; pediatric dosage is derived from adult studies and clinical experience and is not well established. Doses are typically rounded to a convenient amount (eg, <sup>1</sup>/<sub>2</sub> of 81 mg tablet).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute ischemic stroke (AIS) (off-label use):</i> Immediate release: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Noncardioembolic: 1 to 5 mg/kg/dose once daily for &ge;2 years; patients with recurrent AIS or TIAs should be transitioned to clopidogrel, LMWH, or warfarin (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Secondary to Moyamoya and non-Moyamoya vasculopathy: 1 to 5 mg/kg/dose once daily. <b>Note:</b> In non-Moyamoya vasculopathy, continue aspirin for 3 months, with subsequent use guided by repeat cerebrovascular imaging (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Norwood, Fontan surgery (postoperative) (primary prophylaxis) (off-label use):</i> Immediate release: Oral: 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2011]; AHA [Giglia 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prosthetic heart valve (off-label use):</i> Immediate release: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bioprosthetic aortic valve (in normal sinus rhythm): 1 to 5 mg/kg/dose once daily (ACCP [Guyatt 2012]; ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mechanical aortic and/or mitral valve: Low-dose aspirin (eg, 1 to 5 mg/kg/day) combined with vitamin K antagonist (eg, warfarin) is recommended as first-line antithrombotic therapy (ACCP [Guyatt 2012]). Alternative regimens: 6 to 20 mg/kg/dose once daily in combination with dipyridamole (Bradley 1985; El Makhlouf 1987; LeBlanc 1993; Serra 1987; Solymar 1991).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Shunts: Blalock-Taussig or Glenn (primary prophylaxis) (off-label use):</i> Immediate release: Oral: 1 to 5 mg/kg/dose once daily (AHA [Giglia 2013]; ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transcatheter Atrial Septal Defect (ASD) or Ventricular Septal Defect (VSD) devices (postprocedure prophylaxis) (off-label use):</i> Immediate release: Oral: 1 to 5 mg/kg/dose once daily starting one to several days prior to implantation and continued for at least 6 months. For older children and adolescents, after device closure of ASD, an additional anticoagulant may be given with aspirin for 3 to 6 months, but the aspirin should continue for at least 6 months (AHA [Giglia 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ventricular assist device (VAD) placement (off-label use):</i> Immediate release: Oral: 1 to 5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8 to 48 hours following implantation) (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Kawasaki disease (off-label use):</b> Immediate release: Limited data available; optimal dose not established. <b>Note:</b> Patients with Kawasaki disease and presenting with influenza or viral illness should not receive aspirin; acetaminophen is suggested as an antipyretic in these patients and an alternate antiplatelet agent suggested for a minimum of 2 weeks (AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial therapy (acute phase): Recommended dosing regimens vary. Use in combination with IV immune globulin (within first 10 days of symptom onset) and corticosteroids in some cases.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>High dose</i>: 80 to 100 mg/kg/<b>day</b> divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AAP [<i>Red Book</i> 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Moderate dose:</i> 30 to 50 mg/kg/<b>day</b> divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Subsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/<b>day</b> once daily; reported dosing range: 1 to 5 mg/kg/day; initiate after fever resolution (or after 14 days). In patients without coronary artery abnormalities, administer the lower dose for 6 to 8 weeks. In patients with coronary artery abnormalities, low-dose aspirin should be continued indefinitely (in addition to therapy with warfarin) (AAP [<i>Red Book</i> 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatic fever (off-label use):</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 100 mg/kg/day divided into 4 to 5 doses; if response inadequate, may increase dose to 125 mg/kg/day; continue for 2 weeks; then decrease dose to 60 to 70 mg/kg/day in divided doses for an additional 3 to 6 weeks (WHO Guidelines 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Migratory polyarthritis, with carditis without cardiomegaly or congestive heart failure:</i> Initial: 100 mg/kg/day in 4 divided doses for 3 to 5 days, followed by 75 mg/kg/day in 4 divided doses for 4 weeks (Kliegman 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Carditis and cardiomegaly or congestive heart failure:</i> At the beginning of the tapering of the prednisone dose, aspirin should be started at 75 mg/kg/day in 4 divided doses for 6 weeks (Kliegman 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137099\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137100\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Analgesia or anti-inflammatory uses:</i> The manufacturer recommends avoiding in patients with CrCl &lt;10 mL/minute. However, may use with caution and monitor renal function or consider the use of an alternative analgesic/anti-inflammatory agent (NKF [Henrich 1996], Whelton 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Antiplatelet uses:</i> The manufacturer recommends avoiding in patients with CrCl &lt;10 mL/minute. However, in general, the benefit of low-dose aspirin outweighs any risk associated with nephropathy or other adverse effects even in the setting of severe renal impairment; the recommended aspirin dose should not be reduced in any patient with suspected or documented ACS, other cardiovascular disease, or other antithrombotic indication (Fernandez 2001, Harter 1979, Summaria 2015). In patients with diabetes and chronic kidney disease or in dialysis patients, the National Kidney Foundation recommends the use of antithrombotic doses of aspirin (ie, 75 to 162 mg daily) for prevention and management of ischemic heart disease or primary prevention of atherosclerotic disease (KDOQI 2005, KDOQI 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: Dialyzable (concentration dependent; higher salicylate concentrations are more readily dialyzable: 50% to 60%) (Juurlink 2015; Rosenberg 1981); consider administration after hemodialysis on dialysis days (Aronoff 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137101\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid use in severe liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137065\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, oral: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Extra Strength: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Genuine Aspirin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Women's Low Dose Aspirin: 81 mg [contains elemental calcium 300 mg]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, oral [buffered]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ascriptin Maximum Strength: 500 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Plus Extra Strength: 500 mg [contains calcium carbonate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, enteric coated, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Regular Strength: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule Extended Release, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Durlaza: 162.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository, rectal: 300 mg (12s); 600 mg (12s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aspercin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aspirtab: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Genuine Aspirin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral [buffered]: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ascriptin Regular Strength: 325 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buffasal: 325 mg [contains magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bufferin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bufferin Extra Strength: 500 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buffinol: 324 mg [sugar free; contains magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tri-Buffered Aspirin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, chewable, oral: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Children's: 81 mg [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Children's: 81 mg [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">St Joseph Adult Aspirin: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, enteric coated, oral: 81 mg, 325 mg, 650 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aspir-low: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Adult Low Strength: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin Arthritis Strength: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin Low Strength: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Halfprin: 81 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">St Joseph Adult Aspirin: 81 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137050\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137069\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablets: Do not crush enteric-coated tablet. Administer with food or a full glass of water to minimize GI distress. In situations for which a rapid onset of action is required (eg, acute treatment of MI), have patient chew immediate-release tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preeclampsia (prevention):</i> Administration as an evening dose may be more beneficial than administration in the morning (Ayala 2013; Rolnik 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsules: Do not cut, crush, or chew. Administer with a full glass of water at the same time each day. Do not administer 2 hours before or 1 hour after alcohol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Remove suppository from plastic packet and insert into rectum as far as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137068\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Immediate release: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesic/Antipyretic:</b> For the temporary relief of headache, pain, and fever caused by colds, muscle aches and pains, menstrual pain, toothache pain, and minor aches and pains of arthritis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Revascularization procedures:</b> In patients who have undergone revascularization procedures (ie, coronary artery bypass graft [CABG], percutaneous transluminal coronary angioplasty, or carotid endarterectomy). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid disease:</b> For the relief of the signs and symptoms of rheumatoid arthritis (RA), juvenile idiopathic arthritis (formerly called juvenile RA), osteoarthritis, spondyloarthropathies, and arthritis and pleurisy associated with systemic lupus erythematosus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vascular indications (ischemic stroke, transient ischemic attack, acute myocardial infarction, prevention of recurrent myocardial infarction, unstable angina, and chronic stable angina):</b> To reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli; to reduce the risk of vascular mortality in patients with a suspected acute myocardial infarction (MI); to reduce the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina; to reduce the combined risk of MI and sudden death in patients with chronic stable angina.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Extended-release capsules: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic coronary artery disease:</b> To reduce the risk of death and MI in patients with chronic coronary artery disease (eg, history of MI, unstable angina, or chronic stable angina). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>History of ischemic stroke or transient ischemic attack: </b>To reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack (TIA).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Do not use extended-release capsules in situations for which a rapid onset of action is required (such as acute treatment of MI or before percutaneous coronary intervention); use immediate-release formulations instead.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475122\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute coronary syndromes (ST-elevation MI, non-ST-elevation MI, unstable angina); Acute ischemic stroke/transient ischemic attack; Atrial fibrillation (prevention of thromboembolism); Carotid artery stenosis (asymptomatic); Colorectal cancer risk reduction (primary/secondary prevention); Colorectal cancer risk reduction in hereditary nonpolyposis colon cancer carriers (Lynch syndrome); Kawasaki disease; Percutaneous coronary intervention; Pericarditis; Pericarditis associated with MI; Peripheral arterial disease; Polycythemia vera; Preeclampsia (prevention); Prevention (primary) of cardiovascular disease; Prevention (secondary) of cardiovascular disease (patients with diabetes); Prevention (secondary) after CABG surgery; Prosthetic heart valve (thromboprophylaxis); Venous thromboembolism, extended therapy to prevent recurrence (in patients who have completed anticoagulation treatment and decided to stop oral anticoagulation); Aortic valve repair (thromboprophylaxis); Blalock-Taussig or Glenn shunt placement (primary prophylaxis); Fontan or Norwood surgery (primary prophylaxis); Peripheral artery percutaneous transluminal angioplasty; Peripheral artery bypass graft surgery; Rheumatic fever; Transcatheter atrial septal defect (ASD) or ventricular septal defect (VSD) devices (postprocedure prophylaxis); Ventricular assist device (VAD) placement</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137154\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aspirin may be confused with Afrin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ascriptin may be confused with Aricept</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin may be confused with Edecrin, Epogen</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Halfprin may be confused with Haltran</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZORprin may be confused with Zyloprim</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cartia [multiple international markets] may be confused with Cartia XT brand name for dilTIAZem [US]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Aspirin, when used chronically at doses more than 325 mg, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, when aspirin is used for the primary prevention of cardiac events, it should be used with caution in older adults 80 years and older due to a lack of evidence of benefit versus risk (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137057\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs which may affect hemostasis, bleeding is associated with aspirin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables including dosage, concurrent use of multiple agents which alter hemostasis, and patient susceptibility. Many adverse effects of aspirin are dose related, and are rare at low dosages. Other serious reactions are idiosyncratic, related to allergy or individual sensitivity. Accurate estimation of frequencies is not possible. The reactions listed below have been reported for aspirin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Cardiac arrhythmia, edema, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, cerebral edema, coma, confusion, dizziness, fatigue, headache, hyperthermia, insomnia, lethargy, nervousness, Reye's syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, dehydration, hyperglycemia, hyperkalemia, hypernatremia (buffered forms), hypoglycemia (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastrointestinal ulcer (6% to 31%), duodenal ulcer, dyspepsia, epigastric distress, gastritis, gastrointestinal erosion, heartburn, nausea, stomach pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Postpartum hemorrhage, prolonged gestation, prolonged labor, proteinuria, stillborn infant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, blood coagulation disorder, disseminated intravascular coagulation, hemolytic anemia, hemorrhage, iron deficiency anemia, prolonged prothrombin time, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis (reversible), hepatotoxicity, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Acetabular bone destruction, rhabdomyolysis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Hearing loss, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, interstitial nephritis, renal failure (including cases caused by rhabdomyolysis), renal insufficiency, renal papillary necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchospasm, dyspnea, hyperventilation, laryngeal edema, noncardiogenic pulmonary edema, respiratory alkalosis, tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Low birth weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Anorectal stenosis (suppository), atrial fibrillation (toxicity), cardiac conduction disturbance (toxicity), cerebral infarction (ischemic), cholestatic jaundice, colitis, colonic ulceration, coronary artery vasospasm, delirium, esophageal obstruction, esophagitis (with esophageal ulcer), hematoma (esophageal), macular degeneration (age-related) (Li 2014), periorbital edema, rhinosinusitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137072\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to NSAIDs; patients with asthma, rhinitis, and nasal polyps; use in children or teenagers for viral infections, with or without fever.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for salicylates is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137054\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tinnitus: Discontinue use if tinnitus or impaired hearing occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Upper gastrointestinal (UGI) events (eg, symptomatic or complicated ulcers): Low-dose aspirin for cardioprotective effects is associated with a two- to fourfold increase in UGI events. The risks of these events increase with increasing aspirin dose; during the chronic phase of aspirin dosing, doses &gt;81 mg are not recommended unless indicated (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dehydration: Use with caution in patients with dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Heavy ethanol use (&gt;3 drinks/day) can increase bleeding risks and may enhance gastric mucosal damage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with erosive gastritis. Avoid use in patients with active peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in severe hepatic failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: When using high dosages (eg, analgesic or anti-inflammatory uses), use with caution and monitor renal function or consider the use of an alternative analgesic/anti-inflammatory agent (NKF [Henrich 1996]; Whelton 2000). Low-dose aspirin (eg, 75 to 162 mg daily) may be safely used in patients with any degree of renal impairment (KDOQI 2005; KDOQI 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alteplase: In the treatment of acute ischemic stroke, avoid aspirin for 24 hours following administration of alteplase; administration within 24 hours increases the risk of hemorrhagic transformation (Jauch 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; COX-2 inhibitors/NSAIDs: When used concomitantly with &le;325 mg of aspirin, NSAIDs (including selective COX-2 inhibitors) substantially increase the risk of gastrointestinal complications (eg, ulcer); concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower GI bleed patients: An individualized and multidisciplinary approach should be used to manage patients with an acute lower GI bleed (LGIB) who are on antiplatelet medications. Aspirin for primary prevention of cardiovascular events should be avoided in most patients with LGIB who do not have established cardiovascular disease and do not have high risk factors for cardiovascular events. However, aspirin for secondary cardiovascular prevention should generally <i>not </i>be discontinued in patients with established cardiovascular disease and a history of lower GI bleeding (Strate 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: When used for self-medication (OTC labeling): Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients should be instructed to contact their healthcare provider if these occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Aspirin should be avoided (if possible) in surgical patients for 1 to 2 weeks prior to elective surgery, to reduce the risk of excessive bleeding. In patients with cardiac stents or who have recently (within the previous 14 days) undergone balloon angioplasty that have not completed their full course of antiplatelet therapy (eg, dual antiplatelet therapy), antiplatelet therapy should be continued and elective surgery should be delayed until course of antiplatelet therapy is complete; patient specific situations should be discussed with cardiologist (ACC/AHA [Fleisher 2014]; ACC/AHA [Levine 2016]; AHA/ACC/SCAI/ACS/ADA [Grines 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance: Aspirin resistance is defined as measurable, persistent platelet activation that occurs in patients prescribed a therapeutic dose of aspirin. Clinical aspirin resistance, the recurrence of some vascular event despite a regular therapeutic dose of aspirin, is considered aspirin treatment failure. Proposed mechanisms of aspirin resistance include poor adherence with therapy, poor absorption, inadequate dosage, drug interactions, increased isoprostane activity, platelet hypersensitivity to agonists, increased COX-2 activity, COX-1 polymorphism, and platelet alloantigen 2 polymorphism of platelet glycoprotein IIIa. Estimates of biochemical aspirin resistance range from 5.5% to 60% depending on the population studied and the assays used (Gasparyan 2008). Patients with aspirin resistance may have a higher risk of cardiovascular events compared to those who are aspirin sensitive (Gum 2003). Aspirin resistance is likely dose-related but may be influenced by dynamic factors yet to be identified; further research is required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137138\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137059\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8907&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Aspirin. Specifically, alcohol may increase the bleeding risk of aspirin. Alcohol (Ethyl) may diminish the therapeutic effect of Aspirin. Specifically, alcohol may interfere with the controlled release mechanism of extended release aspirin. Management: Monitor patients who drink 3 or more alcoholic drinks a day for increased bleeding while taking aspirin. Counsel patients about the risk of bleeding and discourage such consumption. Give extended release aspirin 2 hours before, or 1 hour after, alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Aspirin may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzbromarone: Salicylates may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.  Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carisoprodol: Aspirin may increase serum concentrations of the active metabolite(s) of Carisoprodol. Specifically, Meprobamate concentrations may be increased. Aspirin may decrease the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Aspirin may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling states that low dose aspirin could be considered, but the use of antiplatelets are not recommended for stroke prevention in patients with atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Aspirin may enhance the adverse/toxic effect of Dexibuprofen. Dexibuprofen may diminish the cardioprotective effect of Aspirin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen.  Management: The use of high-dose salicylates (3 g/day or more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Aspirin may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Aspirin may enhance the anticoagulant effect of Heparin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: Aspirin may diminish the therapeutic effect of Lesinurad. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Aspirin may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, aspirin may decrease the absorption of ascorbic acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, aspirin may decrease the absorption of ascorbic acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Aspirin may enhance the adverse/toxic effect of Nicorandil. Specifically, the risk of gastrointestinal ulceration and hemorrhage may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Aspirin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Phosphate: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: Salicylates may diminish the therapeutic effect of Probenecid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Aspirin may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of other Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: Salicylates may decrease the serum concentration of Sulfinpyrazone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: Aspirin may enhance the adverse/toxic effect of Talniflumate.  Management: When possible, consider alternatives to this combination.  Concurrent use is generally not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Aspirin may decrease the protein binding of Thiopental. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in adult patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in adults receiving ticagrelor.  Canadian recommendations are to avoid adult daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiludronate: Aspirin may decrease the serum concentration of Tiludronate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Salicylates may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137088\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food may decrease the rate but not the extent of oral absorption. Benedictine liqueur, prunes, raisins, tea, and gherkins have a potential to cause salicylate accumulation. Fresh fruits containing vitamin C may displace drug from binding sites, resulting in increased urinary excretion of aspirin. Curry powder, paprika, licorice; may cause salicylate accumulation. These foods contain 6 mg salicylate/100 g. An ordinary American diet contains 10-200 mg/day of salicylate. Management: Administer with food or large volume of water or milk to minimize GI upset. Limit curry powder, paprika, licorice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137075\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Salicylates have been noted to cross the placenta and enter fetal circulation. Adverse effects reported in the fetus include mortality, intrauterine growth retardation, salicylate intoxication, bleeding abnormalities, and neonatal acidosis. Use of aspirin close to delivery may cause premature closure of the ductus arteriosus. Adverse effects reported in the mother include anemia, hemorrhage, prolonged gestation, and prolonged labor (&Oslash;stensen 1998).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Low-dose aspirin may be used to prevent preeclampsia in women with a history of early-onset preeclampsia and preterm delivery (&lt;34 0/7 weeks), or preeclampsia in &ge;1 prior to pregnancy (ACOG 2013). Treatment is started after 12 weeks' gestation in women at risk for preeclampsia (ACCP [Bates 2012]; LeFevre 2014). Low-dose aspirin is used to treat complications resulting from antiphospholipid syndrome in pregnancy (either primary or secondary to SLE) (ACCP [Bates 2012]; Carp 2004; Tincani 2003). Low-dose aspirin to prevent thrombosis may also be used during the second and third trimesters in women with prosthetic valves (mechanical or bioprosthetic). The use of warfarin is recommended, along with low-dose aspirin, in those with mechanical prosthetic valves (AHA/ACC [Nishimura 2014]). Low-dose aspirin may also be used after the first trimester in women with low-risk conditions requiring antiplatelet therapy (AHA/ASA [Kernan 2014]). When needed in doses required for the management of pain, agents other than aspirin are preferred in pregnant women and use in the third trimester is not recommended (K&auml;ll&eacute;n 2016; Shah 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137076\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylic acid is present in breast milk following maternal use of aspirin (Bailey 1982; Findlay 1981; Jamali 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The relative infant dose (RID) of aspirin is 8% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 90 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The RID of aspirin was calculated using a milk concentration of 48.1 mcg/mL, providing an estimated daily infant dose via breast milk of 7.2 mg/kg/day. This milk concentration was obtained following maternal administration of aspirin 1,500 mg as a single dose (Jamali 1981). The reported time to peak milk concentration is variable (2 to 9 hours), milk concentrations decline slowly, and do not correlate strongly to maternal serum concentration (Bailey 1982; Bar-Oz 2003; Findlay 1981; Jamali 1981). Salicylate is measurable in the serum (Unsworth 1987) and urine (Clark 1981) of breastfed infants following maternal use of oral aspirin. Higher salicylate concentrations may be present in breast milk following multiple maternal doses. In addition, salicylate concentrations may be higher than reported as metabolite concentrations of salicylic acid were not evaluated in most studies; the longer elimination half-life in infants compared to adults should also be considered (Bar-Oz 2003; Spigset 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Metabolic acidosis was reported in a 16-day old breastfed full-term infant following maternal doses of aspirin 3.9 g/day (Clark 1981). Thrombocytopenic purpura was also reported in one infant following salicylate exposure via breast milk (Spigset 2000). There were no cases of diarrhea, drowsiness, or irritability noted in breastfed infants in the study which included 15 mother-infant pairs following aspirin exposure (dose, duration, and relationship to breastfeeding not provided) (Ito 1993).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Breastfeeding is not recommended by the manufacturer. When a nonopioid analgesic is needed in postpartum women who wish to breastfeed, agents other than aspirin are preferred (Montgomery 2012). The WHO considers occasional doses of aspirin to be compatible with breastfeeding, but recommends to avoid long-term therapy and consider monitoring the infant for adverse effects (hemolysis, prolonged bleeding, metabolic acidosis) (WHO 2002). Other sources suggest avoiding aspirin while breastfeeding due to the theoretical risk of Reye syndrome (Bar-Oz 2003; Spigset 2000). When used for vascular indications, breastfeeding may be continued during low-dose aspirin therapy (ACCP [Bates 2012]; AHA/ASA [Kernan 2014]; WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137066\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Timing of serum samples: Peak levels usually occur 2 hours after ingestion. Salicylate serum concentrations correlate with the pharmacological actions and adverse effects observed. The serum salicylate concentration (mcg/mL) and the corresponding clinical correlations are as follows: See table. </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Serum Salicylate: Clinical Correlations</caption>\n      <col align=\"center\"></col>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Serum Salicylate Concentration </p>\n            <p style=\"text-indent:0em;\">(mcg/mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Desired Effects</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Adverse Effects / Intoxication</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">~100</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Antiplatelet</p>\n            <p style=\"text-indent:0em;\">Antipyresis</p>\n            <p style=\"text-indent:0em;\">Analgesia</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">GI intolerance and bleeding, hypersensitivity, hemostatic defects</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150-300</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Anti-inflammatory</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Mild salicylism</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250-400</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Treatment of rheumatic fever</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Nausea/vomiting, hyperventilation, salicylism, flushing, sweating, thirst, headache, diarrhea, and tachycardia</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;400-500</p></td>\n          <td align=\"left\"></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Respiratory alkalosis, hemorrhage, excitement, confusion, asterixis, pulmonary edema, convulsions, tetany, metabolic acidosis, fever, coma, cardiovascular collapse, renal and respiratory failure</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137053\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Irreversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, via acetylation, which results in decreased formation of prostaglandin precursors; irreversibly inhibits formation of prostaglandin derivative, thromboxane A<sub>2</sub>, via acetylation of platelet cyclooxygenase, thus inhibiting platelet aggregation; has antipyretic, analgesic, and anti-inflammatory properties </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137071\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Immediate release: Platelet inhibition: Within 1 hour (nonenteric-coated). Onset of enteric-coated aspirin expected to be delayed (Eikelboom 2012). <b>Note:</b> Chewing nonenteric-coated or enteric-coated tablets results in inhibition of platelet aggregation within 20 minutes; therefore, nonenteric-coated tablets should be chewed in settings where a more rapid onset is required (eg, acute MI) and enteric-coated tablets may be chewed when a rapid effect is required and immediate release nonenteric-coated tablets are not available (Eikelboom 2012; Feldman 1999; Sai 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immediate release: 4 to 6 hours; however, platelet inhibitory effects last the lifetime of the platelet (~10 days) due to its irreversible inhibition of platelet COX-1 (Eikelboom 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Immediate release: Rapidly absorbed in stomach and upper intestine (Eikelboom 2012); Extended-release capsule: Rate of absorption is dependent upon food, alcohol, and gastric pH.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 10 L; readily into most body fluids and tissues; hydrolyzed to salicylate (active) by esterases in the GI mucosa, red blood cells, synovial fluid and blood</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Concentration dependent; as salicylate concentration increases, protein binding decreases: ~90% to 94% (to albumin) at concentrations &le;80 mcg/mL (Rosenberg 1981; Juurlink 2015); ~30% with concentrations seen in overdose (Juurlink 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hydrolyzed to salicylate (active) by esterases in GI mucosa, red blood cells, synovial fluid, and blood; metabolism of salicylate occurs primarily by hepatic conjugation; metabolic pathways are saturable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Immediate release: 50% to 75% reaches systemic circulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Parent drug: Plasma concentration: 15 to 20 minutes; Salicylates (dose dependent): 3 hours at lower doses (300 to 600 mg), 5 to 6 hours (after 1 g), 10 hours with higher doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Immediate release: ~1 to 2 hours (nonenteric-coated), 3 to 4 hours (enteric-coated) (Eikelboom 2012); Extended-release capsule: ~2 hours. <b>Note:</b> Chewing nonenteric-coated tablets results in a time to peak concentration of 20 minutes (Feldman 1999). Chewing enteric-coated tablets results in a time to peak concentration of 2 hours (Sai 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (75% as salicyluric acid, 10% as salicylic acid)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137074\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Durlaza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">162.5 mg (30): $216.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (36): $1.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (St Joseph Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (36): $1.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Stanback Headache Powders Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">650-200-32 mg (6): $1.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Aspirin Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (12): $17.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (12): $18.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Aspir-Low Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (250): $6.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (120): $2.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $1.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Bayer Aspirin EC Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (32): $2.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Ecotrin Maximum Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (75): $6.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (EcPirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $2.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Miniprin Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (120): $3.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ascriptin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $7.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $2.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bayer Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (200): $10.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bufferin Extra Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (65): $6.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bufferin Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (130): $5.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bufferin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (65): $4.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137078\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AAS (AR, BR, ES);</li>\n      <li>Acard (PL);</li>\n      <li>Aceprin (HK, MY);</li>\n      <li>Acetard (FI);</li>\n      <li>Aceticil (BR);</li>\n      <li>Acetysal (BG);</li>\n      <li>Acitab (MX);</li>\n      <li>Adiprin (KW, QA);</li>\n      <li>Adiprin EC (JO);</li>\n      <li>Adiro (ES, MX, VE);</li>\n      <li>Albyl-E (NO);</li>\n      <li>Algina (PY);</li>\n      <li>Andol (HR);</li>\n      <li>Ansin (TW);</li>\n      <li>Antacsal-E (MX);</li>\n      <li>Anthrom (PH);</li>\n      <li>Aptor (ID);</li>\n      <li>Artebin (KR);</li>\n      <li>Asactal (HU);</li>\n      <li>Asam (LK);</li>\n      <li>Asapor (FI);</li>\n      <li>Asawin (CO);</li>\n      <li>Ascardia (ID);</li>\n      <li>ASP (HK);</li>\n      <li>Aspa (TW);</li>\n      <li>Aspec (LK, NZ);</li>\n      <li>Aspen (PH);</li>\n      <li>Aspenorm (UA);</li>\n      <li>Aspent (TH);</li>\n      <li>Aspex (IL);</li>\n      <li>Aspicard (ET, KW, SA);</li>\n      <li>Aspicot (KW, LB);</li>\n      <li>Aspilets (ID, PH, VN);</li>\n      <li>Aspilets EC (PH);</li>\n      <li>Aspimed (AE);</li>\n      <li>Aspin (BD, LK);</li>\n      <li>Aspinal (EG, QA);</li>\n      <li>Aspirax (RO);</li>\n      <li>Aspire (TW);</li>\n      <li>Aspirem (BB, BM, BS, BZ, CY, GY, JM, PR, SR, TT);</li>\n      <li>Aspirin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Aspirin Bayer (HK);</li>\n      <li>Aspirin Cardio (IL, SG);</li>\n      <li>Aspirina (CL, CO, CU, EC);</li>\n      <li>Aspirina efervescente (MX);</li>\n      <li>Aspirina Junior (MX);</li>\n      <li>Aspitor (PH);</li>\n      <li>Aspro (AT, CH, CZ, FR, GB, IT, KW, NL, NZ, SA);</li>\n      <li>Aspro Junior (QA);</li>\n      <li>Asprovit (EE);</li>\n      <li>Asrina (TH);</li>\n      <li>ASS (DE);</li>\n      <li>Asthromed (PH);</li>\n      <li>Astrix (HU, KR, LK, PH);</li>\n      <li>B-Aspirin (TH);</li>\n      <li>Bamyl (SE);</li>\n      <li>Bayaspirin Protect 100 (CN);</li>\n      <li>Bayaspirina (AR);</li>\n      <li>Bayer Aspirin Cardio (ZA);</li>\n      <li>Bayprin EC (PH);</li>\n      <li>Besprin (PH);</li>\n      <li>Bokey (SG, TW);</li>\n      <li>Bufferin (JO, UY);</li>\n      <li>Cafemol Childrens Size (ZW);</li>\n      <li>Caprin (GB, IE);</li>\n      <li>Cardioaspirina (CO, PE);</li>\n      <li>Cardiomagnyl (UA);</li>\n      <li>Cardioprin (HR, TW);</li>\n      <li>Cardioprin 100 (IL);</li>\n      <li>Cardioton (PE);</li>\n      <li>Cardiprin (HK, LK);</li>\n      <li>Cartia (PT);</li>\n      <li>Caspirin (MY);</li>\n      <li>Circlevein (KR);</li>\n      <li>Colfarit (CZ, HN);</li>\n      <li>Comoprin (TH);</li>\n      <li>Cortal (PH);</li>\n      <li>Dispril (AE, BE, BH, CY, EG, IQ, IR, JO, LB, LY, OM, QA, SA, SY, TR, YE);</li>\n      <li>Disprin (BB, BF, BJ, BM, BS, BZ, CI, ET, GB, GH, GM, GN, GY, HK, IE, IN, JM, KE, KW, LR, MA, ML, MR, MU, MW, NE, NG, NZ, PK, PR, SC, SD, SG, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Ecasil (BR);</li>\n      <li>Ecorin (LK);</li>\n      <li>Ecosprin (BD);</li>\n      <li>Ecotrin (AR, CL, MX, NZ, TW);</li>\n      <li>Encine EM (TW);</li>\n      <li>Eskotrin (VE);</li>\n      <li>Frosit (ID);</li>\n      <li>Globentyl (DK);</li>\n      <li>Glocar (ID);</li>\n      <li>Godamed (IL);</li>\n      <li>Kardegic (HU);</li>\n      <li>Kidiprin (JO);</li>\n      <li>Lodosprin (BD);</li>\n      <li>Lopirin (TW);</li>\n      <li>Magnecyl (SE);</li>\n      <li>Melabon (DE);</li>\n      <li>Micropirin (MT);</li>\n      <li>Miniaspi 80 (ID);</li>\n      <li>Naspro (ID);</li>\n      <li>Neospin (BD);</li>\n      <li>Norspirinal (ID);</li>\n      <li>Novasen (KW);</li>\n      <li>Nu-Seals (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, YE, ZM, ZW);</li>\n      <li>Nuasa (IE);</li>\n      <li>Nuprin (IE);</li>\n      <li>Plaquetasa (CR, GT, SV);</li>\n      <li>Proprin (GB);</li>\n      <li>Remin (AE);</li>\n      <li>Rhonal (KR, QA, VE);</li>\n      <li>Rodin (UA);</li>\n      <li>Salisalido (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Salospir (GR);</li>\n      <li>Sedergine (BE);</li>\n      <li>Tevapirin (IL);</li>\n      <li>Thomapyrin (AT);</li>\n      <li>Thrombo-Aspilets (ID);</li>\n      <li>Thrombo-ASS (EE);</li>\n      <li>Tromcor (PH);</li>\n      <li>V-AS (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22315275\"></a>Alonso-Coello P, Bellmunt S, McGorrian C, et al; American College of Chest Physicians. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 suppl):e669S-e690S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315275/pubmed\" target=\"_blank\" id=\"22315275\">22315275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Kimberlin DW, Brady MT, Jackson MA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24150027\"></a>American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/29222380/pubmed\" target=\"_blank\" id=\"29222380\">29222380</a>]</span><span class=\"doi\">10.2337/dc18-S009</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi: 10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armstrong MJ, Gronseth G, Anderson DC, et al. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2013;80(22):2065-2069.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23713086/pubmed\" target=\"_blank\" id=\"23713086\">23713086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007;20-136.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. <i>Chronobiol Int.</i> 2013;30(1-2):260-279. doi: 10.3109/07420528.2012.717455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23004922/pubmed\" target=\"_blank\" id=\"23004922\">23004922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey DN, Weibert RT, Naylor AJ, Shaw RF. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. <i>J Anal Toxicol</i>. 1982;6(2):64-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/7098450/pubmed\" target=\"_blank\" id=\"7098450\">7098450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barbui T, Barosi G, Birgegard G,et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. <i>J Clin Oncol.</i> 2011;29(6):761-770. doi: 10.1200/JCO.2010.31.8436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/21205761/pubmed\" target=\"_blank\" id=\"21205761\">21205761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barbui T, Finazzi G. Evidence-based management of polycythemia vera.<i> Best Pract Res Clin Haematol.</i> 2006;19(3):483-493.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/16781485/pubmed\" target=\"_blank\" id=\"16781485\">16781485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Bulkowstein M, Benyamini L, et al, &ldquo;Use of Antibiotic and Analgesic Drugs During Lactation,&rdquo; <i>Drug Saf</i>, 2003, 26(13):925-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/14583068/pubmed\" target=\"_blank\" id=\"14583068\">14583068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates ER, Babb JD, Casey DE Jr, et al, &ldquo;ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting),&rdquo; <i>J Am Coll Cardiol</i>, 2007, 49(1):126-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/17207736/pubmed\" target=\"_blank\" id=\"17207736\">17207736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 Suppl):e691S-e736S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22621626\"></a>Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. [Erratum in <i>N Engl J Med</i>. 2012;367(16):1573.] <i>N Engl J Med</i>. 2012;366(21):1959-1967. doi: 10.1056/NEJMoa1114238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22621626/pubmed\" target=\"_blank\" id=\"22621626\">22621626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7234652\"></a>Berman J, Haffajee CI, and Alpert JS, &ldquo;Therapy of Symptomatic Pericarditis After Myocardial Infarction: Retrospective and Prospective Studies of Aspirin, Indomethacin, Prednisone, and Spontaneous Resolution,&rdquo; <i>Am Heart J</i>, 1981, 101(6):750-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/7234652/pubmed\" target=\"_blank\" id=\"7234652\">7234652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>J Am Coll Cardiol</i>, 2008, 52(18):1502-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley LM, Midgley FM, Watson DC, et al, &ldquo;Anticoagulation Therapy in Children With Mechanical Prosthetic Cardiac Valves,&rdquo; <i>Am J Cardiol</i>, 1985, 56(8):533-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/4036839/pubmed\" target=\"_blank\" id=\"4036839\">4036839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Branch DW and Khamashta MA, &ldquo;Antiphospholipid Syndrome: Obstetric Diagnosis, Management, and Controversies,&rdquo; <i>Obstet Gynecol</i>, 2003, 101(6):1333-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/12798544/pubmed\" target=\"_blank\" id=\"12798544\">12798544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23121403\"></a>Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. <i>N Engl J Med</i>. 2012;367(21):1979-1987. doi: 10.1056/NEJMoa1210384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23121403/pubmed\" target=\"_blank\" id=\"23121403\">23121403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22036019\"></a>Burn J, Gerdes AM, Macrae F, et al; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. <i>Lancet</i>. 2011;378(9809):2081-2087.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22036019/pubmed\" target=\"_blank\" id=\"22036019\">22036019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calonge N, Petitti DB, DeWitt TG, et al, &ldquo;Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. U.S Preventive Services Task Force,&rdquo; <i>Ann Intern Med</i>, 2009, 150(6):396-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/19293072/pubmed\" target=\"_blank\" id=\"19293072\">19293072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo; <i>J Am Coll Cardiol</i>, 2005, 45(8):1295-1301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15837265/pubmed\" target=\"_blank\" id=\"15837265\">15837265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carp HJ, &ldquo;Antiphospholipid Syndrome in Pregnancy,&rdquo; <i>Curr Opin Obstet Gynecol</i>, 2004, 16(2):129-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15017341/pubmed\" target=\"_blank\" id=\"15017341\">15017341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo; <i>N Engl J Med</i>, 2001, 345(25):1809-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/11752357/pubmed\" target=\"_blank\" id=\"11752357\">11752357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. <i>Clin Pediatr (Phila)</i>. 1981;20(1):53-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/7449246/pubmed\" target=\"_blank\" id=\"7449246\">7449246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;CLASP: A Randomised Trial of Low-Dose Aspirin for the Prevention and Treatment of Pre-eclampsia Among 9364 Pregnant Women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group,&quot; <i>Lancet</i>, 1994, 343(8898):619-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/7906809/pubmed\" target=\"_blank\" id=\"7906809\">7906809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16765759\"></a>Connolly S, Pogue J, Hart R, et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. <i>Lancet</i>. 2006;367(9526):1903-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/16765759/pubmed\" target=\"_blank\" id=\"16765759\">16765759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22041946\"></a>Connolly SJ, Eikelboom JW, Ng J, et al; ACTIVE (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med. 2011;1;155(9):579-586. doi: 10.7326/0003-4819-155-9-201111010-00004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22041946/pubmed\" target=\"_blank\" id=\"22041946\">22041946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19336502\"></a>Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. <i>N Engl J Med</i>. 2009;360(20):2066-2078.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/19336502/pubmed\" target=\"_blank\" id=\"19336502\">19336502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coomarasamy A, Honest H, Papaioannou S, et al, &ldquo;Aspirin for Prevention of Preeclampsia in Women With Historical Risk Factors: A Systematic Review,&rdquo; <i>Obstet Gynecol</i>, 2003, 101(6):1319-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/12798543/pubmed\" target=\"_blank\" id=\"12798543\">12798543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo; <i>Clin Ther</i>, 2005, 27(2):185-191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15811481/pubmed\" target=\"_blank\" id=\"15811481\">15811481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Csuka ME, McCarty DJ. Aspirin and the treatment of rheumatoid arthritis. <i>Rheum Dis Clin North Am</i>. 1989;15(3):439-454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/2672131/pubmed\" target=\"_blank\" id=\"2672131\">2672131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation. <i>Neurology</i>. 2014;82:716-724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/24566225/pubmed\" target=\"_blank\" id=\"24566225\">24566225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department of Health and Human Services, Food and Drug Administration, &ldquo;Labeling for Oral and Rectal Over-the-Counter Drug Products Containing Aspirin and Nonaspirin Salicylates; Reye's Syndrome Warning; Final Rule, (29 CFR Part 201),&rdquo; <i>Fed Regist</i>, April 17, 2003, 18861-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/10177739/pubmed\" target=\"_blank\" id=\"10177739\">10177739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Desjardins PJ, Cooper SA, Gallegos TL, et al, &ldquo;The Relative Analgesic Efficacy of Propiram Fumarate, Codeine Aspirin, and Placebo in Post-Impaction Dental Pain,&rdquo; <i>J Clin Pharmacol</i>, 1984, 24(1):35-42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durlaza (aspirin) [prescribing information]. North Haven, CT: New Haven Pharmaceuticals; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012:141(2)(supp):e89S-e119S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315278/pubmed\" target=\"_blank\" id=\"22315278\">22315278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    el Makhlouf A, Friedli B, Oberh&auml;nsli I, et al, &ldquo;Prosthetic Heart Valve Replacement in Children: Results and Follow-up of 273 Patients,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 1987, 93(1):80-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/3796033/pubmed\" target=\"_blank\" id=\"3796033\">3796033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. <i>Am J Cardiol</i>. 1999;84(4):404-409.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/10468077/pubmed\" target=\"_blank\" id=\"10468077\">10468077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez JS, Sadaniantz A. Medical and revascularization management in acute coronary syndrome in renal patients. <i>Semin Nephrol</i>. 2001;21(1):25-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/11172556/pubmed\" target=\"_blank\" id=\"11172556\">11172556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo; <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23098967/pubmed\" target=\"_blank\" id=\"23098967\">23098967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findlay JW, DeAngelis RL, Kearney MF, Welch RM, Findlay JM. Analgesic drugs in breast milk and plasma. <i>Clin Pharmacol Ther</i>. 1981;29(5):625-633.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/7214793/pubmed\" target=\"_blank\" id=\"7214793\">7214793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi: 10.1161/CIR.0000000000000105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25085962/pubmed\" target=\"_blank\" id=\"25085962\">25085962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forbes JA, Butterworth GA, Burchfield WH, et al, &ldquo;Evaluation of Ketorolac, Aspirin, and an Acetaminophen-Codeine Combination in Postoperative Oral Surgery Pain,&rdquo; <i>Pharmacotherapy</i>, 1990, 10(6 Pt 2):77S-93S.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forbes JA, Keller CK, Smith JW, et al, &ldquo;Analgesic Effect of Naproxen Sodium, Codeine, a Naproxen-Codeine Combination and Aspirin on the Postoperative Pain of Oral Surgery,&rdquo; <i>Pharmacotherapy</i>, 1986, 6(5):211-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gasparyan AY, Watson T, Lip GYH. The role of aspirin in cardiovascular prevention; implications of aspirin resistance. <i>Am J Coll Cardiol</i>. 2008;51(9):1829-1843.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/18466797/pubmed\" target=\"_blank\" id=\"18466797\">18466797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27851992\"></a>Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. <i>J Am Coll Cardiol. </i>2017;69(11):e71-e126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/27851992/pubmed\" target=\"_blank\" id=\"27851992\">27851992</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/24226806/pubmed\" target=\"_blank\" id=\"24226806\">24226806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grines CL, Bonow RO, Casey DE, et al, &ldquo;AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the American College of Physicians,&rdquo; Circulation, 2007, 115(6):813-8. Available at http://circ.ahajournals.org/cgi/content/full/115/6/813. doi: 10.1161/CIRCULATIONAHA.106.180944.17224480</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gum PA, Kottke-Marchant K, Welsh PA, et al,&ldquo;A Prospective, Blinded Determination of the Natural History of Aspirin Resistance Among Stable Patients With Cardiovascular Disease,&rdquo; <i>J Am Coll Cardiol</i>, 2003, 41(6):961-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/12651041/pubmed\" target=\"_blank\" id=\"12651041\">12651041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. <i>New Eng J Med</i>. 1979;301(11):577-579.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/112475/pubmed\" target=\"_blank\" id=\"112475\">112475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. <i>Am J Kidney Dis</i>. 1996;27(1):162-165.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/8546133/pubmed\" target=\"_blank\" id=\"8546133\">8546133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo; <i>Circulation </i>, 2006, 113(11):e463-654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/16549646/pubmed\" target=\"_blank\" id=\"16549646\">16549646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurlen M, Erikssen J, Smith P, et al, &ldquo;Comparison of Bleeding Complications of Warfarin and Warfarin Plus Acetylsalicylic Acid: A Study in 3166 Outpatients,&rdquo; <i>J Intern Med</i>, 1994, 236(3):299-304.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19673674\"></a>Imazio M, Brucato A, Trinchero R, et al, &ldquo;Individualized Therapy for Pericarditis,&rdquo; <i>Expert Rev Cardiovasc Ther</i>, 2009, 7(8):965-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/19673674/pubmed\" target=\"_blank\" id=\"19673674\">19673674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15028364\"></a>Imazio M, Demichelis B, Parrini I, et al, &ldquo;Day-Hospital Treatment of Acute Pericarditis,&rdquo; <i>J Am Coll Cardiol</i>, 2004, 43(6):1042-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15028364/pubmed\" target=\"_blank\" id=\"15028364\">15028364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jamali F, Keshavarz E. Salicylate excretion in breast milk. <i>Int J Pharm</i>. 1981;8:285-290.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeske AH, Suchko GD, ADA Council on Scientific Affairs and Division of Science, et al, &ldquo;Lack of a Scientific Basis for Routine Discontinuation of Oral Anticoagulation Therapy Before Dental Treatment,&rdquo; <i>J Am Dent Assoc</i>, 2003, 134(11):1492-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/14664269 /pubmed\" target=\"_blank\" id=\"14664269 \">14664269 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juurlink DN, Gosselin S, Kielstein JT, et al; EXTRIP Workgroup. Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP Workgroup. <i>Ann Emerg Med</i>. 2015;66(2):165-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25986310/pubmed\" target=\"_blank\" id=\"25986310\">25986310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Reis M. Ongoing pharmacological management of chronic pain in pregnancy. <i>Drugs</i>. 2016;76(9):915-924.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/27154242/pubmed\" target=\"_blank\" id=\"27154242\">27154242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. <i>Am J Kidney Dis</i>. 2005;45(4 suppl 3):S1-S153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15806502/pubmed\" target=\"_blank\" id=\"15806502\">15806502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. <i>Am J Kidney Dis</i>. 2007;49(2 suppl 2):S12-S154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/17276798/pubmed\" target=\"_blank\" id=\"17276798\">17276798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Brady MT, Jackson MA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Geme JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulik A, Ruel M, Jneid H, et al; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131 (10):927-964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25679302/pubmed\" target=\"_blank\" id=\"25679302\">25679302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeBlanc JG, Sett SS, and Vince DJ, &ldquo;Antiplatelet Therapy in Children With Left-Sided Mechanical Prostheses,&rdquo; <i>Eur J Cardiothorac Surg</i>, 1993, 7(4):211-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/8481259/pubmed\" target=\"_blank\" id=\"8481259\">8481259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeFevre ML; US Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: US Preventive Services Task Force recommendation statement. <i>Ann Intern Med</i>. 2014;161(11):819-826.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25200125/pubmed\" target=\"_blank\" id=\"25200125\">25200125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2016;68(10):1082-1115. doi: 10.1016/j.jacc.2016.03.513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/27036918/pubmed\" target=\"_blank\" id=\"27036918\">27036918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy G. Clinical Pharmacokinetics of Aspirin. <i>Pediatrics</i>. 1978;62(5, pt 2)(suppl):867-872.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/724339/pubmed\" target=\"_blank\" id=\"724339\">724339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li L, Li W, Chen CZ, Yi ZH, Zhou YY. Is aspirin use associated with age-related macular degeneration? A meta-analysis. <i>J Clin Pharm Ther</i>. 2015, 40(2):144-154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25475899/pubmed\" target=\"_blank\" id=\"25475899\">25475899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maalouf R, Mosley M, Kallail J, et al, &ldquo;A Comparison of Salicylic Acid Levels in Normal Subjects After Rectal versus Oral Dosing,&rdquo; <i>Acad Emerg Med</i>, 2009, 16(2):157-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/19076101/pubmed\" target=\"_blank\" id=\"19076101\">19076101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin CP and Talbert RL,&ldquo;Aspirin Resistance: An Evaluation of Current Evidence and Measurement Methods,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(7):942-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/16006273/pubmed\" target=\"_blank\" id=\"16006273\">16006273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMullin MF, Bareford D, Campbell P, et al; General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. <i>Br J Haematol</i>. 2005;130(2):174-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/16029446/pubmed\" target=\"_blank\" id=\"16029446\">16029446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Medeiros FB, de Andrade AC, Angelis GA, et al, &quot;Bleeding Evaluation During Single Tooth Extraction in Patients With Coronary Artery Disease and Acetylsalicylic Acid Therapy Suspension: A Prospective, Double-Blinded, and Randomized Study,&quot; <i>J Oral Maxillofac Surg</i>, 2011, 69(12):2949-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/21802823/pubmed\" target=\"_blank\" id=\"21802823\">21802823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meher S, Duley L, Hunter K, et al. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. <i>Am J Obstet Gynecol.</i> 2017;216(2):121-128.e2. doi: 10.1016/j.ajog.2016.10.016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/27810551/pubmed\" target=\"_blank\" id=\"27810551\">27810551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meschia JF, Bushnell C, Boden-Albala B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014;45(12):3754-3832.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25355838/pubmed\" target=\"_blank\" id=\"25355838\">25355838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan A, Goldenberg NA, et al, &quot;Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),&quot; <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Cochrane A, Roberts R, et al, &ldquo;A Multicenter, Randomized Trial Comparing Heparin/Warfarin and Acetylsalicylic Acid as Primary Thromboprophylaxis for 2 Years after the Fontan Procedure in Children,&rdquo; <i>J Am Coll Cardiol</i>, 2011, 58(6):645-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/21798429/pubmed\" target=\"_blank\" id=\"21798429\">21798429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. <i>Pediatrics</i>. 2004; 114(6):1708-1733<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15574639/pubmed\" target=\"_blank\" id=\"15574639\">15574639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M, Khamashta M, Lockshin M, &quot;Anti-inflammatory and Immunosuppressive Drugs and Reproduction,&quot; <i>Arthritis Res Ther</i>, 2006, 8(3):209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/16712713/pubmed\" target=\"_blank\" id=\"16712713\">16712713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M, &ldquo;Nonsteroidal Anti-inflammatory Drugs During Pregnancy,&rdquo; <i>Scand J Rheumatol Suppl</i>, 1998, 107:128-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/9759151/pubmed\" target=\"_blank\" id=\"9759151\">9759151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Physician's Health Study: Aspirin and Primary Prevention of Coronary Heart Disease,&rdquo; <i>N Engl J Med</i>, 1989, 321(26):1825-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/2594041/pubmed\" target=\"_blank\" id=\"2594041\">2594041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ridker PM, Cook NR, Lee IM, et al, &quot;A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women,&quot; <i>N Engl J Med</i>, 2005, 352(13):1293-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15753114/pubmed\" target=\"_blank\" id=\"15753114\">15753114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. <i>Am J Obstet Gynecol.</i> 2017;216(2):110-120.e6. doi: 10.1016/j.ajog.2016.09.076.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/27640943/pubmed\" target=\"_blank\" id=\"27640943\">27640943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberge S, Odibo AO, Bujold E. Aspirin for the prevention of preeclampsia and intrauterine growth restriction. <i>Clin Lab Med.</i> 2016;36(2):319-329. doi: 10.1016/j.cll.2016.01.013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/27235915/pubmed\" target=\"_blank\" id=\"27235915\">27235915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rolnik DL, Wright D, Poon LC et al . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. <i>N Engl J Med.</i> 2017. doi: 10.1056/NEJMoa1704559. [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/28657417/pubmed\" target=\"_blank\" id=\"28657417\">28657417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rooke TW, Hirsch AT, Misra S, et al, &ldquo;2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(18):2020-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/21959305/pubmed\" target=\"_blank\" id=\"21959305\">21959305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenberg J, Benowitz NL, Pond S. Pharmacokinetics of drug overdose. <i>Clin Pharmacokinet</i>. 1981;6(3):161-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/7016383/pubmed\" target=\"_blank\" id=\"7016383\">7016383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20970847\"></a>Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. <i>Lancet</i>. 2010;376(9754):1741&ndash;1750.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/20970847/pubmed\" target=\"_blank\" id=\"20970847\">20970847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sai Y, Kusaka A, Imanishi K, et al. A randomized, quadruple crossover single-blind study on immediate action of chewed and unchewed low-dose acetylsalicylic acid tablets in healthy volunteers. <i>J Pharm Sci</i>. 2011;100(9):3884-3891.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/21544823/pubmed\" target=\"_blank\" id=\"21544823\">21544823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanderson S, Emery J, Baglin T, et al, &quot;Narrative Review: Aspirin Resistance and Its Clinical Implications,&quot; <i>Ann Intern Med</i>, 2005, 142(5):370-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/15738456/pubmed\" target=\"_blank\" id=\"15738456\">15738456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12621132\"></a>Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. <i>N Engl J Med</i>. 2003;348(10):883-890.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/12621132/pubmed\" target=\"_blank\" id=\"12621132\">12621132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&ouml;mig A, Neumann FJ, Kastrati A, et al, &ldquo;A Randomized Comparison of Antiplatelet and Anticoagulant Therapy After the Placement of Coronary-Artery Stents,&rdquo; <i>N Engl J Med</i>, 1996, 334(17):1084-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/8598866/pubmed\" target=\"_blank\" id=\"8598866\">8598866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serra AJ, McNicholas KW, Olivier HF Jr, et al, &ldquo;The Choice of Anticoagulation in Pediatric Patients With the St. Jude Medical Valve Prostheses,&rdquo; <i>J Cardiovasc Surg</i>, 1987, 28(5):588-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/3654744/pubmed\" target=\"_blank\" id=\"3654744\">3654744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah S, Banh ET, Koury K, Bhatia G, Nandi R, Gulur P. Pain management in pregnancy: multimodal approaches. <i>Pain Res Treat</i>. 2015;2015:987483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/26448875/pubmed\" target=\"_blank\" id=\"26448875\">26448875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25156992\"></a>Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. <i>Circulation</i>. 2014;130(13):1062-1071. doi: 10.1161/CIRCULATIONAHA.114.008828.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25156992/pubmed\" target=\"_blank\" id=\"25156992\">25156992</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solymar L, Rao PS, Mardini MK, et al, &ldquo;Prosthetic Valves in Children and Adolescents,&rdquo; <i>Am Heart J</i>, 1991, 121(2 Pt 1):557-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/1990763/pubmed\" target=\"_blank\" id=\"1990763\">1990763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O and Hagg S, &ldquo;Analgesics and Breast-Feeding: Safety Considerations,&rdquo; <i>Paediatr Drugs</i>, 2000, 2(3):223-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/10937472/pubmed\" target=\"_blank\" id=\"10937472\">10937472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines [Published online ahead of print Dec 1, 2014]. <i>J Clin Oncol</i>. 2014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/25452455/pubmed\" target=\"_blank\" id=\"25452455\">25452455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Summaria F, Giannico MB, Talarico GP, Patrizi R. Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. <i>Nephrourol Mon</i>. 2015;7(4):e28099.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/26528445/pubmed\" target=\"_blank\" id=\"26528445\">26528445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tincani A, Branch W, Levy RA, et al, &ldquo;Treatment of Pregnant Patients With Antiphospholipid Syndrome,&rdquo; <i>Lupus</i>, 2003, 12(7):524-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/12892392/pubmed\" target=\"_blank\" id=\"12892392\">12892392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Unsworth J, d'Assis-Fonseca A, Beswick DT, Blake DR. Serum salicylate levels in a breast fed infant. <i>Ann Rheum Dis</i>. 1987;46(8):638-639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/3662653/pubmed\" target=\"_blank\" id=\"3662653\">3662653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: Clinical Summary. AHRQ Publication No.09-05129-EF-3, March 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.uspreventiveservicestaskforce.org/uspstf09/aspirincvd/aspcvdsum.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      U.S. Preventive Services Task Force. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Clinical Summary. AHRQ Publication No. 14-05207-EF-4, September 2014. Agency for Healthcare Research and Quality, Rockville, MD. http://www.uspreventiveservicestaskforce.org/uspstf14/asprpreg/asprpregsumm.htm25200125</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandvik PO, Lincoff AM, Gore JM, et al; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2 suppl):e637S-e668S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315274/pubmed\" target=\"_blank\" id=\"22315274\">22315274</a>]</span><span class=\"doi\">10.1378/chest.11-2306</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. <i>Am J Ther</i>. 2000;7(2):63-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/11319575/pubmed\" target=\"_blank\" id=\"11319575\">11319575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation. Geneva, Switzerland: World Health Organization; 2004. http://www.who.int/cardiovascular_diseases/resources/en/cvd_trs923.pdf. Accessed December 15, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23451245\"></a>Ye X, Fu J, Yang Y, et al. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8(2):e57578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/23451245/pubmed\" target=\"_blank\" id=\"23451245\">23451245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22315271\"></a>You JJ, Singer DE, Howard PA, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e531S-e575S. doi: 10.1378/chest.11-2304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-drug-information/abstract-text/22315271/pubmed\" target=\"_blank\" id=\"22315271\">22315271</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8907 Version 221.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137093\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F137094\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F137145\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F137098\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F137119\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F137099\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F137100\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F137101\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137065\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F137050\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F137069\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F137068\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475122\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F137154\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137057\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137072\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137054\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F137138\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137059\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F137088\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F137075\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F137076\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F137066\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137053\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F137071\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F137074\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F137078\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8907|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aspirin-patient-drug-information\" class=\"drug drug_patient\">Aspirin: Patient drug information</a></li><li><a href=\"topic.htm?path=aspirin-pediatric-drug-information\" class=\"drug drug_pediatric\">Aspirin: Pediatric drug information</a></li></ul></div></div>","javascript":null}